[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633328":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":48,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Yale University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hepatology Clinicians","EXPERIMENTAL","Clinician participants will participate in a multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested. Participants will attend two approximately 60-minute-long educational sessions in which key points related to AUD treatment based on the HPCR resource and implementation facilitation intervention will be reviewed.",[13],"Behavioral: Implementation Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","Implementation Intervention","A multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Lamia Haque","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Lamia Haque, MD MPH","CONTACT","(203) 777-0304","lamia.haque@yale.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":20},"Yale School of Medicine\u002FYale-New Haven Health","RECRUITING","New Haven","Connecticut","06520","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-72.92816,41.30815,{"lat":44,"lon":43},{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[49],{"name":50,"class":51},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH","100633328","implementation-facilitation-pilot-for-alcohol-use-disorder-aud-in-alcohol-associated-liver-disease-ald-100633328",false,"NCT07525258","Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)","Feasibility and Acceptability of a Novel Implementation Intervention to Promote Alcohol Use Disorder Treatment in Hepatology Clinics","Inclusion Criteria:\n\n* Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.\n\nExclusion Criteria:\n\n* Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.",true,"ALL","18 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"NA","The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.",[70,71],"Alcohol Use Disorder","Alcohol-associated Liver Disease",[73,74],"Clinicians","Medications for Alcohol Use Disorder","2026-05-05",{"date":77,"type":78},"2026-05-07","ACTUAL",{"date":80,"type":78},"2026-04-05",{"date":82,"type":64},"2029-04",{"name":5,"class":6},1]